Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
NASDAQ Composite
Standard & Poors 500
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
957.76
+5.36 (+0.56%)
Delayed Quote
Updated: 4:00 PM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
↗
November 17, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a...
Via
MarketBeat
Topics
ETFs
Intellectual Property
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
↗
November 14, 2026
The stock has climbed more than 40% in one year.
Via
The Motley Fool
S&P 500 Premarket Movers: Gainers and Losers Ahead of the Open
↗
November 11, 2026
Via
Chartmill
Topics
Stocks
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%
↗
November 10, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced...
Via
MarketBeat
Topics
ETFs
Regeneron Pharmaceuticals (NASDAQ:REGN) Looks Undervalued Under the Decent Value Framework
↗
November 03, 2026
Via
Chartmill
S&P 500 Unusual Volume Movers for Nov. 2, 2026
↗
November 02, 2026
Via
Chartmill
Topics
Stocks
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
↗
November 08, 2026
These are among the best the industry has to offer.
Via
The Motley Fool
Topics
Intellectual Property
3 cash-producing stocks walking a fine line
November 04, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
1 Nasdaq 100 stock on our buy list and 2 facing challenges
November 02, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via
StockStory
Stock Market Today: Intel’s Worst Day in Four Decades Drags Chips and the Nasdaq to a Rough October Finish
↗
November 02, 2026
Via
Chartmill
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Beat Driven by Dupixent Growth
↗
October 30, 2026
Via
Chartmill
Topics
Earnings
The top 5 analyst questions from Regeneron’s Q3 earnings call
November 01, 2026
Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street’s reve...
Via
StockStory
Topics
Earnings
Regeneron: 3 Key Takeaways for Long-Term Investors
↗
October 31, 2026
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Via
The Motley Fool
Topics
Earnings
REGN Q3 deep dive: pipeline progress and core brands drive outperformance
October 31, 2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. I...
Via
StockStory
S&P 500 Top Movers: Gainers and Losers in Today's US Session
↗
October 30, 2026
Via
Chartmill
Topics
Stocks
S&P 500 Top Movers: Gainers and Losers in Today's Session
↗
October 30, 2026
Via
Chartmill
Topics
Stocks
Regeneron (REGN) stock trades up, here is why
October 30, 2026
What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-qua...
Via
StockStory
Topics
Artificial Intelligence
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
↗
October 30, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company...
Via
MarketBeat
Topics
ETFs
Earnings
Regeneron (REGN) Q3 2026 Earnings Call Transcript
↗
October 30, 2026
Dupixent, EYLEA HD, and Libtayo hit record sales, fueling record earnings growth.
Via
The Motley Fool
Topics
Earnings
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026
↗
October 30, 2026
Via
Chartmill
Topics
Stocks
Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soars
October 30, 2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 36.3% year on year to $5.12 billion....
Via
StockStory
What to expect from Regeneron’s (REGN) Q3 earnings
October 29, 2026
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. Regeneron beat a...
Via
StockStory
1 safe-and-steady stock with exciting potential and 2 facing headwinds
October 23, 2026
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...
Via
StockStory
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
↗
October 19, 2026
Is this company the biggest dark horse in the chronic weight management space?
Via
The Motley Fool
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
↗
October 17, 2026
Regeneron's biggest growth driver still has plenty of fuel left in the tank.
Via
The Motley Fool
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
October 14, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...
Via
StockStory
Topics
Artificial Intelligence
Top S&P500 movers in Wednesday's session
↗
October 14, 2026
Via
Chartmill
Discover which S&P500 stocks are making waves on Monday.
↗
October 12, 2026
Via
Chartmill
Why Regeneron (REGN) Stock Is Trading Lower Today
October 01, 2026
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all...
Via
StockStory
Which S&P500 stocks are moving on Thursday?
↗
October 01, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.